115 results
Page 2 of 6
8-K
EX-99.1
tnpax j5bxlx59
9 Nov 22
Zai Lab Announces Third Quarter 2022
4:13pm
8-K
EX-99.1
mt4q6f
27 Sep 22
Entry into a Material Definitive Agreement
8:08am
8-K
EX-99.1
ativ2 0nd
9 Aug 22
Zai Lab Announces Second Quarter 2022
12:00am
8-K
EX-99.1
2xzsz4dec 5bc
10 May 22
Zai Lab Announces First Quarter 2022
4:10pm
8-K
EX-99.1
7snyydguk 4fn51spj67
21 Apr 22
Zai Lab Announces Engagement of KPMG LLP, a U.S. Auditor, as the Company’s Independent Registered Public Accounting Firm
7:34am
8-K
EX-99.1
sgzfy7qc0pzze 99pbdh
15 Mar 22
Zai Lab Announces the Appointment of Josh Smiley as Chief Operating Officer
8:31am
8-K
EX-99.1
anf4xx6f hc99w
1 Mar 22
Results of Operations and Financial Condition
4:17pm
CORRESP
p2dgz5
14 Jan 22
Correspondence with SEC
12:00am
8-K
EX-99.1
seal8f e6r92rojfgm
6 Jan 22
Zai Lab Announces NDA Acceptance of
7:44am
8-K
EX-99.1
fc7 y44q5928w7
22 Dec 21
Zai Lab announces promotion of Harald Reinhart M.D. to President and Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases
4:14pm
8-K
EX-99.1
giqxz4yhfrya8 haudj
16 Dec 21
China NMPA Approves NUZYRA® as a Category 1
7:43am
8-K
EX-99.1
zbbvvc8o62i2wf11w 0v
3 Dec 21
Zai Lab Announces Inclusion of ZEJULA® (Niraparib) in China’s National Reimbursement Drug List for First-Line Ovarian Cancer
7:45am
8-K
EX-99.1
ngxcc yivbhvn5lvltw
22 Nov 21
Zai Lab Appoints Richard Gaynor, MD, to its Board of Directors
7:40am
8-K
EX-99.2
c6uvy54wp bwf2goz
9 Nov 21
Zai Lab and Blueprint Medicines Announce Strategic Collaboration and License
4:26pm
8-K
EX-99.3
4fhhyuoapjsqb
9 Nov 21
Zai Lab and Blueprint Medicines Announce Strategic Collaboration and License
4:26pm
8-K
EX-99.1
ms9xl
9 Nov 21
Zai Lab and Blueprint Medicines Announce Strategic Collaboration and License
4:26pm